Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 4/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026883 | 0.92 | ESR1 (0.44) | MPOESR1NR1H2NR1H3GPR139 | |
| SCHEMBL4025766 | 0.87 | MPO (0.47) | MPOSMPD1TLR8ADORA3GPR139 | |
| SCHEMBL4025973 | 0.86 | ESR1 (0.59) | MPOESR1NR1H2NR1H3ADORA3 | |
| SCHEMBL4025992 | 0.79 | ESR1 (0.69) | MPOESR1SMPD1TLR8ADORA3 | |
| SCHEMBL4029516 | 0.78 | TNKS (0.46) | ESR1NR1H2NR1H3ADORA3GPR139 | |
| SCHEMBL4200871 | 0.77 | NR1H2 (0.43) | NR1H2NR1H3ADORA3GPR139MAOB | |
| SCHEMBL4031615 | 0.77 | ESR1 (0.62) | ESR1NR1H2NR1H3NR1I2NR3C1 | |
| SCHEMBL4033022 | 0.75 | ACACA (0.45) | NR1H2NR1H3ADORA3MEN1KMT2A | |
| SCHEMBL1407179 | 0.75 | CRHR1 (0.40) | ESR1TLR8CRHR1 | |
| SCHEMBL4031736 | 0.74 | HTR2A (0.45) | MPOGPR139MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1542976-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Wyeth (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004031159-A1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | MPO 944/4885ESR1 1028/4885SMPD1 3985/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | MPO 1067/4885ESR1 2487/4885SMPD1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.